This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fichtner-Feigl, S. Articles by Strober, W. Search for Related Content PubMed PubMed Citation Articles by Fichtner-Feigl, S. Articles by Strober, W.

Restoration of Tumor Immunosurveillance via Targeting of Interleukin-13 Receptor-₂

¹ Department of Surgery, University of Regensburg, Regensburg, Germany; and ² Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases and ³ Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Stefan Fichtner-Feigl, Department of Surgery, University of Regensburg Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. Phone: 49-941-9440; Fax: 49-941-944-6802; E-mail: stefan.fichtner{at}klinik.uni-regensburg.de.

Key Words: cytotoxicity • IL-13Receptor-2 • metastasis

In previous studies, we described a "counter-immunosurveillance" mechanism initiated by tumor-activated, interleukin-13 (IL-13)–producing natural killer T cells that signal Gr-1⁺ cells to produce transforming growth factor-β₁ (TGF-β₁), a cytokine that suppresses the activity of tumor-inhibiting cytolytic CD8⁺ T cells. Here, we show that in two tumor models (the CT-26 metastatic colon cancer and the 15-12RM fibrosarcoma regressor models), this counter-surveillance mechanism requires the expression of a novel IL-13 receptor, IL-13R₂, on Gr-1^intermediate cells, because down-regulation of IL-13R₂ expression or the activator protein-1 signal generated by the receptor via in vivo administration of specific small interfering RNA or decoy oligonucleotides leads to loss of TGF-β₁ production. Furthermore, acting on prior studies showing that IL-13R₂ expression is induced (in part) by tumor necrosis factor- (TNF-), we show that receptor expression and TGF-β₁ production is inhibited by administration of a TNF-–neutralizing substance, TNF-R-Fc (etanercept). Taking advantage of this latter fact, we then show in the CT-26 model that counter-immunosurveillance can be inhibited, anti-CT-26–specific CD8⁺ cytolytic activity can be restored, and CT-26 metastatic tumor nodules can be greatly decreased by administration of TNF-R-Fc. Corroborative data were obtained using the 15-12RM fibrosarcoma model. These studies point to the prevention of metastatic cancer with an available agent with already known clinically acceptable adverse effects and toxicity. [Cancer Res 2008;68(9):3467–75]

This article has been cited by other articles:

				S. Ostrand-Rosenberg and P. Sinha Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer J. Immunol., April 15, 2009; 182(8): 4499 - 4506. [Abstract] [Full Text] [PDF]